Actively Recruiting
Evaluating E6742 Oral Tablets Compared to Placebo for Systemic Lupus Erythematosus Treatment A Phase 2 Randomized, Double-Blind, Multicenter Dose-Response Study
Led by Eisai Co., Ltd. · Updated on 2026-08-21
256
Participants Needed
54
Research Sites
29 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of E6742, an oral drug, compared with a placebo in adults with systemic lupus erythematosus SLE. This phase 2, randomized, double-blind, placebo-controlled study aims to assess how different doses of E6742 influence the proportion of participants achieving a response using the British Isles Lupus Assessment Group BILAG based Composite Lupus Assessment BICLA while using a low dose of oral corticosteroids at Week 24. Participants will be randomly assigned to receive one of several doses of E6742 or a placebo in oral tablet form. The treatment period involves administering these doses while monitoring participants for up to 24 weeks. The study evaluates the efficacy based on dose response, as well as safety measures including adverse events, laboratory tests, vital signs, and various clinical assessments during this time. Throughout the study, participants will undergo multiple evaluations including clinical assessments like SLEDAI-2K, BILAG-2004, patient-reported outcomes, and laboratory tests such as autoantibody levels and complements. Safety will be monitored via vital signs, ECGs, ophthalmic exams, and chest X-rays. The primary outcome is measured at Week 24, with safety and secondary outcomes assessed up to 52 weeks. Participants are expected to comply with study visits and treatments over this period.
CONDITIONS
Brief Title
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Research Team
E
Eisai Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here